PATIENT Act of 2023

Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; H.R. 10337, Expanding the Health Care Workforce Act; and H.R. 4392, Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025.

Client expense: $150,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1, the One Big, Beautiful Bill Act H.R. 2433, Reducing Medically Unnecessary Delays in Care Act of 2025 Improving seniors' timely access to care act (S. 1816 / H.R. 3514) Genomic Data Protection Act Tariffs S. 998, Medical Supply Chain Resiliency Act S 106 / HR 539 - Chiropractic Medicare Coverage Modernization Act PAMA reform HR 2483, Support for Patients and Communities Reauth Act HR 2484, Seniors access to Critical medications act Reducing Hereditary Cancer Act S 1399, the Health Tech Investment Act H.R. 3580, the Oversight of Medicare Billing Code Cost Act S 1830 - the Right to Treat Act S 1811 - Prohibits Graduate medical schools from receiving Federal assistance if DEI policies are in place S. 1916 - Protect Genetic information after bankruptcy S 1830 - HHS has no authority to regulate the practice of medicine S 2066, Medicare transaction Fraud prevention act LCD legislation S 1866 - National Breast and Cervical Cancer Early Detection Program S 1882 - to expand research and training on reproductive health conditions HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 H.R. 10073, Medicare patient Access and Practice Stabilization Act of 2024 S. 4935, Physician Fee Stabilization Act H.R. 5392, The Timely Access to Coverage Decisions Act of 2023 Medical Lab Personnel Shortage Relief Act H.R. 9572 Enhanced Enforcement of Health Coverage Act Sickle Cell Disease Comprehensive Care Act S. 709/H.R. 1585 - Conrad State 30 and Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes. H.R. 1968 - Continuing Resolution H.R. 1201 - Doctors in our Borders Act Issues relating to regulation of laboratory diagnostics Patent Eligibility Restoration Act CDC Division of Cancer Prevention and Control and cancer registries appropriations S. 2439 and H.R. 4731, Resident Physician Shortage Reduction Act H.R.5371 - Continuing Appropriations and Extensions Act, 2026 HR 3164 - Ensuring Community Access to Pharmacy Services Act (ECAPS) S 2800 - Pharmacy and Medically Underserved Areas Enhancement Act S 2420 / H.R. 4710 - No Surprises Act Enforcement Act S 2793 - Ensuring Access to Essential Providers Act of 2025 H.R. 5582 / S 2355 - Patients Deserve Price Tags Act Issues related to tariffs Issues related to public health

Client expense: $124,816 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); Medicare site neutrality policies; support of telehealth policies, including for audio-only telehealth services; H.R. 7053/S. 3792 - acute hospital care at home waiver flexibility; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R.3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 5378, the Lower Costs, More Transparency Act; H.R. 5860, the Continuing Appropriations Act, 2024 and Other Extensions Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 7327, the Protecting Front Line Multimission Hospitals Act of 2024; S. 3450, the Mental and Physical Health Care Comorbidities Act of 2023; and H.R. 10337, Expanding the Health Care Workforce Act.

Client expense: $330,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8247, the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2024; H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; and H.R. 10337, Expanding the Health Care Workforce Act.

Client expense: $330,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1, the One Big, Beautiful Bill Act H.R. 2433, Reducing Medically Unnecessary Delays in Care Act of 2025 Seniors timely access to care act (S. 1816 / H.R. 3514) Genomic Data Protection Act Tariffs S. 998, Medical Supply Chain Resiliency Act S 106 / HR 539 - Chiropractic Medicare Coverage Modernization Act PAMA reform HR 2483, Support for Patients and Communities Reauth Act HR 2484, Seniors access to Critical medications act Reducing Hereditary Cancer Act S 1399, the Health Tech Investment Act H.R. 3580, the Oversight of Medicare Billing Code Cost Act S 1830 - the Right to Treat Act S 1811 - Prohibits Graduate medical schools from receiving Federal assistance if DEI policies are in place S. 1916 - Protect Genetic information after bankruptcy S 1830 - HHS has no authority to regulate the practice of medicine S 2066, Medicare transaction Fraud prevention act LCD legislation S 1866 - National Breast and Cervical Cancer Early Detection Program S 1882 - to expand research and training on reproductive health conditions HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 H.R. 10073, Medicare patient Access and Practice Stabilization Act of 2024 S. 4935, Physician Fee Stabilization Act H.R. 5392, The Timely Access to Coverage Decisions Act of 2023 Medical Lab Personnel Shortage Relief Act H.R. 9572 Enhanced Enforcement of Health Coverage Act Sickle Cell Disease Comprehensive Care Act S. 709/H.R. 1585 - Conrad State 30 and Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes. H.R. 1968 - Continuing Resolution H.R. 1201 - Doctors in our Borders Act Issues relating to regulation of laboratory diagnostics Patent Eligibility Restoration Act

Client expense: $149,447 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); Medicare site neutrality policies; support of telehealth policies, including for audio-only telehealth services; H.R. 7053/S. 3792 - acute hospital care at home waiver flexibility; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R.3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 5378, the Lower Costs, More Transparency Act; H.R. 5860, the Continuing Appropriations Act, 2024 and Other Extensions Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 7327, the Protecting Front Line Multimission Hospitals Act of 2024; S. 3450, the Mental and Physical Health Care Comorbidities Act of 2023; and H.R. 10337, Expanding the Health Care Workforce Act.

Client expense: $150,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8247, the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2024; H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; and H.R. 10337, Expanding the Health Care Workforce Act.

Client expense: $150,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act Health Workforce Resilience Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts Cytotechnologist labor rates Remote digital telepathology S 1000/HR 2377 SALSA HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs. HR 1202/S 704 - REDI Act HR2761/S 705 - SPARC Act HR 2764/S1229 - Green New Deal for Health HR 3248 - Diagnostic Lab Testing Transparency Act H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 Student loan repayment for FPs HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act S 1994 Counting Veterans Cancer Act HR 4875 Doctors in our Borders Act HR 2474 - Strengthening Medicare for Patients and Providers Act Continuing Appropriations Act, 2024 and Other Extensions Act Further Continuing Appropriations and Other Extensions Act, 2024 HR 6683 - Preserving Seniors Access to Physicians Act of 2023 Gene Therapy Precision Medicine Answers for Kids Today Act S.3018/H.R.3173 the Improving Seniors Timely Access to Care Act of 2021 Dr. Lorna Breen Health Care Provider Protection Act PREVAIL HR 6371 - budget neutrality bill EDUCATE Act - Murphy DEI Bill HR 2369 - VALID Act FDA final rule on LDTs Pandemic All-Hazards Preparedness Act H.R.9747, the Continuing Appropriations and Extensions Act, 2025 S.2140/H.R. 9474, the Patent Eligibility Restoration Act of 2023 S.1451 / H.R. 3120 - Healthy Competition for Better Care Act H.R. 9572 - Enhanced Enforcement of Health Coverage Act H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act Cures 2.1 H.R. 10073, Medicare patient Access and Practice Stabilization Act of 2024 S. 4935, Physician Fee Stabilization Act H.R. 5392, The Timely Access to Coverage Decisions Act of 2023 Medical Lab Personnel Shortage Relief Act H.R. 9572 Enhanced Enforcement of Health Coverage Act Sickle Cell Disease Comprehensive Care Act S. 709/H.R. 1585 - Conrad State 30 and Physician Access Reauthorization Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes. H.R. 1968 - Continuing Resolution H.R. 1201 - Doctors in our Borders Act Issues relating to regulation of laboratory diagnostics Patent Eligibility Restoration Act

Client expense: $217,588 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

340B Program; Issues related to affordable prescription drugs; Issues related to health care workforce and staffing; Issues related to health care privacy; Issues related to telehealth authorities; Issues related to hospital price transparency; Issues related to hospital reimbursement; Issues related to nonprofit hospital practices; Issues related to hospital outpatient department payments; Issues related to hospital outpatient department payments; Medicaid Disproportionate Share Hospital payment adjustment program; Issues related to Medicare payments; Issues related to Medicare Advantage payment and prior authorization; Childrens Hospital Graduate Medical Education Program (CHGME); issues related to childrens medical care; issues related to rural health; S. 4352/H.R. 8702, the Seniors Timely Access to Care Act H.R. 2584/S. 2768, the Safety From Violence for Healthcare Employees (SAVE) Act; Expanding Care in the Home Act; H.R. 1770, Equitable Access to Pharmacy Services Act; issues related to Program for All-Inclusive Care for the Elderly (PACE); H.R. 1770, Equitable Access to Pharmacy Services Act; H.R. 3008, the Drug Shortage Prevention Act; H.R. 3810, the Drug Origin Transparency Act; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act; issues related to preventing and mitigating drug shortages; H.R. 2389/S. 1302, the Resident Physician Shortage Reduction Act; H.R. 3263, the Support Faculty and Expand Access to Nursing Act; issues related to prior authorization, unwarranted claim denials, and payment delays; S. 2840, the Bipartisan Primary Care and Health Workforce Expansion Act; H.R. 3561, the PATIENT Act; H.R. 6363, Further Continuing Appropriations and Other Extension Act; H.R. 5378, the Lower Costs, More Transparency Act; Issues related to mental and behavioral health; the limit on Medicare payment days for inpatient psychiatric care; the Institutions for Mental Disease exclusion; issues related to extending programs under the SUPPORT for Patients Communities Act; issues related to cybersecurity; enhanced Advanced Premium Tax Credits

Client expense: $750,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to affordable prescription drugs; Issues related to telehealth authorities; Issues related to health care workforce and staffing; Medicaid Disproportionate Share Hospital payment adjustment program; Issues related to Medicaid coverage; Issues related to hospital reimbursement; 340B Program; Issues related to hospital price transparency; Issues related to Medicare payments; Issues related to Medicare Advantage payment and prior authorization; issues related to rural health reimbursement, including the Medicare Dependent Hospital and Low Volume Hospital programs; physician reimbursement rates; S. 4352/H.R. 8702, the Seniors Timely Access to Care Act; issues related to Program for All-Inclusive Care for the Elderly (PACE); issues related to improving coordination of care for dual eligibles; issues related to site neutral payments; H.R. 3281, the Transparent PRICE Act; issues related to prior authorization, unwarranted claim denials, and payment delays; the Biologics Price Competition and Innovation Act (BPCIA); H.R. 3561, the PATIENT Act; H.R. 6363, Further Continuing Appropriations and Other Extension Act; H.R. 5378, the Lower Costs, More Transparency Act; PL 118-42/H.R. 4366 - Consolidated Appropriations Act, 2024; PL 118-47/H.R. 2882 - Consolidated Appropriations Act, 2024; Issues related to mental and behavioral health; the limit on Medicare payment days for inpatient psychiatric care; the Institutions for Mental Disease exclusion; issues related to extending programs under the SUPPORT for Patients Communities Act; H.R. 10545, the American Relief Act

Client expense: $750,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

The 340B Drug Pricing Program; H.R. 2534, The Protect 340B Act; FY24 and FY25 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations bills. HR 3290,to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R.3561 - PATIENT Act of 2023, The Stop Drug Shortages Act (Draft legislation- House), H.R. 5378: Lower Costs, More Transparency Act, S. 1182: 340B Reporting and Accountability Act; S.1133: 340B Accountability Act of 2023,S.1038: Drug Price Transparency in Medicaid Act of 2023,H.R.1613: Drug Price Transparency in Medicaid Act of 2023,H.R.198: Drug Pricing Transparency and Accountability Act; S. 2973: Modernizing and Ensuring PBM Accountability Act, Draft Senate legislation the SUSTAIN 340B Act, HR 7635 and S. 5021, the 340B PATIENTS Act.H.R. 8574, 340B ACCESS Act: H.R.8144 - Rural 340B Access Act of 2024

Client expense: $345,454 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE

Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8247, the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2024; H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; and H.R. 10337, Expanding the Health Care Workforce Act.

Client expense: $150,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); Medicare site neutrality policies; support of telehealth policies, including for audio-only telehealth services; H.R. 7053/S. 3792 - acute hospital care at home waiver flexibility; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R.3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 5378, the Lower Costs, More Transparency Act; H.R. 5860, the Continuing Appropriations Act, 2024 and Other Extensions Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 7327, the Protecting Front Line Multimission Hospitals Act of 2024; S. 3450, the Mental and Physical Health Care Comorbidities Act of 2023; and H.R. 10337, Expanding the Health Care Workforce Act.

Client expense: $150,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R.2665, Supporting Safety Net Hospitals Act H.R.2389, the Resident Physician Shortage Reduction Act of 2023 H.R.3561 - PATIENT Act of 2023 H.R. 3887, the Childrens Hospital GME Support Reauthorization Act of 2023 H.R. 3561, PATIENT Act of 2023 H.R. 5378, The Lower Costs, More Transparency Act S. 2719 Directing our Countrys Transfer of Residency Slots (DOCTORS) Act of 2023 S. 3196 - Ensuring Medicaid Continuity for Children in Foster Care Act H.R. 2829 Chronic Care Management Improvement Act of 2023 H.R. 7397 -Reinforcing Essential Health Systems for Communities Act H.R. 6929 & S.3565, Affordable Connectivity Program Extension Act of 2024 Strengthening Pathways to Health Professions Act Fiscal Year 2025 Children's Hospitals Graduate Medical Education (CHGME) Appropriations Support Issues related to Section 203 of the Consolidated Appropriations Act of 2021 Issues related to the Medicare/Medicaid dual eligible population Issues related to Medicare Site-neutral payment cuts Issues related to Medicaid DSH Cuts

Client expense: $630,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

H.R. 1613 / S. 1038, the Drug Price Transparency in Medicaid Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 1770 / S. 2477, the Equitable Community Access to Pharmacist Services Act; S. 1491, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 2816, the PBM Sunshine and Accountability Act; H.R. 3281, the Transparent PRICE Act; H.R. 3282, the Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3561, the PATIENT Act; S. 1967, the Patients Before Middlemen (PBM) Act; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2973, the Modernizing and Ensuring PBM Accountability Act; H.R. 5378, the Lower Costs, More Transparency Act; H.R.5385, the Medicare PBM Accountability Act; H.R. 5393, to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes; H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program in the Inflation Reduction Act" (IRA; P.L. 117-169); Comments for "Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025" (IRA, P.L. 117-169); Comments for Final Rule Document 2022-09375, "Medicare Program, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs..." (87 FR 27704); Comments for "Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies" (CMS-2024-0006); Request for Information for Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024 H.R.2882, the Further Consolidated Appropriations Act, 2024 Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement; Comments to CMS on the implementation of Medicare Part D vaccine coverage under the Inflation Reduction Act (IRA; P.L. 117-169); Comments to CMMI on the Importance of Implementing Reasonable Reimbursement Guardrails for Pharmacies in the Medicare $2 Drug List Model based on the Executive Order on Lowering Prescription Drug Costs for Americans; Comments to HHS and CMS on 2024 NADAC Methodology Changes; Comment on "Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027.";

Client expense: $340,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Small Business Administration (SBA), White House Office

The 340B Drug Pricing Program; H.R. 2534, The Protect 340B Act; FY24 and FY25 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations bills. HR 3290,to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R.3561 - PATIENT Act of 2023, The Stop Drug Shortages Act (Draft legislation- House), H.R. 5378: Lower Costs, More Transparency Act, S. 1182: 340B Reporting and Accountability Act; S.1133: 340B Accountability Act of 2023,S.1038: Drug Price Transparency in Medicaid Act of 2023,H.R.1613: Drug Price Transparency in Medicaid Act of 2023,H.R.198: Drug Pricing Transparency and Accountability Act; S. 2973: Modernizing and Ensuring PBM Accountability Act, Draft Senate legislation the SUSTAIN 340B Act, HR 7635 and S. 5021, the 340B PATIENTS Act.H.R. 8574, 340B ACCESS Act: H.R.8144 - Rural 340B Access Act of 2024

Client expense: $260,046 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE

Pharmacy Benefit Manager Transparency Act S.127; PBM reform bills; H.R.3561 The PATIENT Act; S.2973 MEPA;

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

340B Program; H.R.2534 Protect 340B Act; 340B Transparency and Oversight H.R.3290/S.1133; The PATIENT Act H.R.3561; Resident Physician Shortage Reduction Act H.R.2389; Preventive Health Savings Act S.114/H.R.766; Safety from Violence for Healthcare Employees "SAVE" Act H.R.2584; H.R.5378 Lower Costs, More Transparency Act; Stop Drug Shortages Act; H.R.5378 Lower Costs, More Transparency Act; Senate 340B RFI - responded; 340B Access Act; Telehealth extenders; The American Relief Act 2025, HR10545

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

340B Program H.R. 3561, PATIENT ACT

Client expense: $164,314 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 485 - Protecting Health Care For All Patients Act of 2023 - Rep. McMorris Rodgers, Cathy - federal programs using prices based on quality-adjusted life years H.R. 824 - Telehealth Benefit Expansion for Workers Act of 2023 - Rep. Walberg, Tim - telehealth and ERISA amendments H.R. 830 - HELP Copays Act - Rep. Carter, Earl - health insurers responsibility for payments made by or on behalf of a plan enrollee toward a plans cost-sharing requirements H.R. 1488 - Affordable Insulin Now Act of 2023 - Rep. Craig, Angie - cost-sharing for insulin products H.R. 2666 - MVP Act - Rep. Guthrie, Brett - value-based purchasing arrangements under Medicaid program and reforms to price reporting H.R. 2691 - Transparent Price Act - Rep. McMorris Rodgers, Cathy - health insurer price transparency H.R. 2813 - Self-Insurance Protection Act - Rep. Good, Bob - ERISA amendments H.R. 2868 - Association Health Plans Act - Rep. Walberg, Tim - ERISA amendments H.R. 3305 - Black Maternal Health Momnibus Act - Rep. Underwood, Lauren - maternal health including in Medicaid and CHIP H.R. 3561 - PATIENT Act - Rep. McMorris Rodgers, Cathy - PBM transparency, PBM contract design, health insurance transparency, hospital transparency H.R. 3799 - Custom Health Option and Individual Care Expense Arrangement Act- Rep. Hern, Kevin - health reimbursement arrangements H.R. 7623 - Telehealth Modernization Act of 2024- Rep. Carter, Buddy - including requirements for Part D plan contracts with PBMs including transparency and delinking provisions H.R. 7858 - Telehealth Enhancement for Mental Health Act of 2024 - Rep. James, John - Medicare, behavioral health, telehealth H.R. 9572 - Enhanced Enforcement of Health Coverage Act - Rep. Murphy, Gregory - increased penalties of surprise billing violations H.R. 10445 - Further Continuing Appropriations and Disaster Relief Supplement Appropriations Act, 2025 - Rep. Cole, Tom - to fund the federal government through March 14, 2025 as well as extension of several health care policies S. 3393 - SUPPORT for Patients and Communities Reauthorization Act. - Sen. Sanders, Bernie - SUD treatment S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 - Sen. Wyden, Ron - mental health, telehealth, health workforce S. 3612 - Access to Family Building Act- Sen. Duckworth, Tammy- right to access reproductive technology (ex. IVF) S. 3805 - A bill to amend title XI of the Social Security Act to prohibit health plans from imposing fees on health care providers for electronic funds transfers and health care payment and remittance advice transactions, and for other purposes. - Sen. Cassidy, Bill - SSA, healthcare, electronic funds, payments, remittance S. 4357 - Comprehensive Dental Reform Act of 2024- Sen. Sanders, Bernie - promotes access to oral health care S. 4358 - Preventing and Treating Substance Use Disorders Among Older Adults Act- Sen. Casey, Robert - SAMHSA grant program for SUDs S. 4554 - Reproductive Freedom for Women Act- Sen. Murray, Patty - protecting abortion and reproductive rights Issues related to broadband and public health infrastructure; mental health and telehealth; behavioral health; rural health; substance use disorder treatments; Health Savings Accounts; provider directories; artificial intelligence and privacy; insurance industry response to and support for providers regarding the Change Healthcare cyberattack and broader cyber security issues; ACA Marketplace; and Mental Health Parity Proposed Rule.

Client expense: $2,610,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Pharmacy Benefit Manager Bills- Pharmacy Benefit Manager Transparency Act (S. 127), PATIENT Act of 2023 (H.R.3561); Bills related to PBM transparency with implications for health plans like those managed by Mutual of Omaha

Client expense: $90,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Support for H.R.7327 - Protecting Front Line Multimission Hospitals Act of 2024. Sustainability of safety net health systems. Social determinants of health. Support of telehealth policies, including for audio-only telehealth services. 340B Protect Act, H.R.4390. H.R.3290, To amend Title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R.2665, Supporting Safety Net Hospitals Act. H.R.3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. Support for policies to enhance health care workforce programs. H.R.5378, Lower Costs, More Transparency Act. S.3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act. S.3450, Mental and Physical Health Care Comorbidities Act of 2023. H.R. 10337, Expanding the Healthcare Workforce Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Funding for Disproportionate Share Hospitals (Medicaid DSH). Support for H.R.7327 - Protecting Front Line Multimission Hospitals Act of 2024. Support of telehealth policies, including for audio-only telehealth services. H.R.7053/S.3792 - acute hospital care at home waiver flexibility. H.R.3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023. H.R.5378, Lower Costs, More Transparency Act; Medicare physician payment reductions, in general. H.R.6545, Physician Fee Schedule Update and Improvements Act. H.R.2474, Strengthening Medicare for Patients and Providers Act. S.3450, Mental and Physical Health Care Comorbidities Act of 2023. H.R. 10073, the Medicare Patient Access and Practice Stabilization Act of 2024. S.4532/H.R. 8702, Improving Seniors Timely Access to Care Act of 2024. In general, support provisions to reform Medicare physician fee schedule payment policies and access to physician services.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program H.R. 456: Fairness in Orphan Drug Exclusivity Act H.R. 766: Dr. Michael C. Burgess Preventive Health Savings Act H.R. 830: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes H.R. 1613: Drug Price Transparency in Medicaid Act of 2023 H.R. 1790: Biologics Competition Act of 2023 - To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes H.R. 2534: PROTECT 340B Act of 2023 - Provisions related to the 340B program H.R. 2679: Pharmacy Benefits Manager Accountability Act H.R. 2707: MADE in America Act H.R. 2816: Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880: Protecting Patients Against PBM Abuses Act H.R. 3290: To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3433: Give Kids a Chance Act of 2024 H.R. 3561: Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or PATIENT Act of 2023 H.R. 3839: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act H.R. 4818: Treat and Reduce Obesity Act of 2023 H.R. 4895: Lowering Drug Costs for American Families Act - Provisions related to drug pricing H.R. 4988: Modern Authentication of Pharmaceuticals Act of 2023 H.R. 5376: Share the Savings with Seniors Act  H.R. 5378: Lower Costs, More Transparency Act H.R. 5391: Protecting Patient Access to Cancer and Complex Therapies Act H.R. 5539: ORPHAN Cures Act H.R. 6283: Delinking Revenue from Unfair Gouging or DRUG Act H.R. 6664: Innovation in Pediatric Drugs Act of 2023 H.R. 7024 Tax Relief for American Families and Workers Act of 2024 H.R. 7174: Ensuring Pathways to Innovative Cures (EPIC) Act: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7248: FDA Modernization Act 3.0 H.R. 7623: Telehealth Modernization Act of 2024 H.R. 7635: The 340B PATIENTS Act of 2024 H.R. 8574: 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act H.R. 9096: Pharmacists Fight Back Act S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs S. 148: Stop STALLING Act - Provisions related to citizen petitions S. 1067: Ensuring Timely Access to Generics Act of 2023 S. 1130: Health Care PRICE Transparency Act S. 1264: SMART Prices Act - Provisions related to drug pricing reform S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes S. 1542: Delinking Revenue from Unfair Gouging Act or DRUG Act - Provisions related to PBMs S. 1589: Safeguarding Patients and Taxpayers Act S. 1967: PBM Act S. 2305: Biosimilar Red Tape Elimination Act S. 2333: Pandemic and All-Hazards Preparedness and Response Act S. 2474: Share the Savings with Seniors Act S. 2477: Equitable Community Access to Pharmacist Services Act S. 2973: Modernizing and Ensuring PBM Accountability Act (MEPA) S. 3393: SUPPORT for Patients and Communities Reauthorization Act S. 3430: Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S. 5021: 340B PATIENTS Act of 2024 S. 5040: Protecting Patients from Deceptive Drugs Online Act S. 5459: Biosimilars Access and Affordability Act BioCompete Act (draft) Executive Order of February 28, 2024, Preventing Access to Americans' Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) User fee policy issues Inflation Reduction Act of 2022 (P.L. 117-169) IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Cancer Moonshot Initiative 21st Century Cures 2.0 Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Accelerated approval policy issues FDA regulatory approval authority policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance (AMR) policy issues Supply chain policy issues Clinical trial diversity policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Pandemic preparedness policy issues Artificial intelligence policy issues Vaccine provisions of the Inflation Reduction Act Policy issues related to vaccines

Client expense: $920,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

H.R. 5391/S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act; Access and reimbursement of Part B Drugs in Medicare; Continued expansion of Telehealth services including in H.R. 3875/S. 3967, Expanded Telehealth Access Act and Telehealth Modernization Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act (PATIENT Act) of 2023; H.R. 4822, Health Care Price Transparency Act of 2023; Support for site neutrality policies in H.R. 5378, Lower Costs, More Transparency Act; Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022; Issues related to MACRA Reform including H.R. 2474, Strengthening Medicare for Patients and Providers Act; Support the passage of H.R. 5526/S. 3458, the Seniors' Access to Critical Medications Act; H.R. 6683, Preserving Seniors Access to Physicians Act of 2023; Issues related to prior authorization in H.R. 8702/S. 4518, Improving Seniors Timely Access to Care Act of 2024; S. 2973, The Modernizing and Ensuring PBM Accountability (MEPA) Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1613 / S. 1038, the Drug Price Transparency in Medicaid Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 1770 / S. 2477, the Equitable Community Access to Pharmacist Services Act; S. 1491, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 2816, the PBM Sunshine and Accountability Act; H.R. 3281, the Transparent PRICE Act; H.R. 3282, the Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3561, the PATIENT Act; S. 1967, the Patients Before Middlemen (PBM) Act; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2973, the Modernizing and Ensuring PBM Accountability Act; H.R. 5378, the Lower Costs, More Transparency Act; H.R.5385, the Medicare PBM Accountability Act; H.R. 5393, to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes; H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program in the Inflation Reduction Act" (IRA; P.L. 117-169); Comments for "Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025" (IRA, P.L. 117-169); Comments for Final Rule Document 2022-09375, "Medicare Program, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs..." (87 FR 27704); Comments for "Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies" (CMS-2024-0006); Request for Information for Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024 H.R.2882, the Further Consolidated Appropriations Act, 2024 Cybersecurity protocols and policies in health care system and the impact on claims processing and reimbursement; Comments to CMS on the implementation of Medicare Part D vaccine coverage under the Inflation Reduction Act (IRA; P.L. 117-169); Comments to CMMI on the Importance of Implementing Reasonable Reimbursement Guardrails for Pharmacies in the Medicare $2 Drug List Model based on the Executive Order on Lowering Prescription Drug Costs for Americans; Comments to HHS and CMS on 2024 NADAC Methodology Changes; Comment to CMS on "Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027."; H.R. 9096, the Pharmacists Fight Back Act; Long Term Care at Home Pharmacy Services in Medicare; Regulating fair and common-sense contracting guardrails between Part D plans/PBMs, and pharmacies; Comments to CMS on Proposed Rule Re: Medicare and Medicaid Programs; CY 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program; and Medicare Overpayments [CMS-1807-P]; H.R.4758, the Accelerating Kids Access to Care Act; H.R. 8107, the Ensuring Access to Medicaid Buy-in Programs Act of 2024; Comments to CMS on Draft Guidance Re: Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027; Request for Information to CMS on "Medicare $2 Drug list Model" (Executive Order 14087 of October 14, 2022); H.R.5074/S.5410, the Kidney PATIENT Act; H.R.4104/S.1976, the Preserving Patient Access to Home Infusion Act; H.R.10545, the American Relief Act, 2025;

Client expense: $412,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Small Business Administration (SBA), White House Office

Issues related to Medicare Part D, Medicare Advantage, Medicaid, mental health, and telehealth. Issues related to COVID testing, vaccination, and treatment. Issues related to Accountable Care Organizations. Issues related to Medicare Shared Savings Program. S. 1339 - Pharmacy Benefit Manager Reform Act of 2023 S. 1967 - Patients Before Middlemen Act of 2023 S. 2973 - Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act H.R. 2679 - Pharmacy Benefit Manager Accountability Act of 2023 H.R. 3285 - Fairness for Patient Medications Act H.R. 1613 - Drug Price Transparency in Medicaid Act of 2023 H.R. 3561 - Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 H.R. 5378 - Lower Costs, More Transparency Act H.R. 2880 - Protecting Patients Against PBM Abuses Act

Client expense: $2,040,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Issues related to Medical Economic Index (MEI) in the 2023 Physician Fee Schedule Rule; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act of 2023; H.R. 3284, Providers and Payers COMPETE Act; H.R. 4822, Health Care Price Transparency Act of 2023; S. 3503, Value in Healthcare Act; SFC white paper entitled, Bolstering Chronic Care through Physician Payment: Current Challenges and Policy Options in Medicare Part B; Issues related to physician payment cuts; H.R. 1770/S. 2477, Equitable Community Access to Pharmacist Services Act; H.R. 10545, American Relief Act, 2025

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues regarding childrens health care coverage and access to care under Medicaid, CHIP, the Exchanges, TRICARE, and private insurance Issues regarding the annual Notice of Benefit and Payment Parameters for the Exchanges and private insurance Issues regarding childrens mental health and the national emergency in childrens mental health, including mental health parity, the mental health workforce and related access issues. Issue regarding Medicaid supplemental payments and directed payments Issues related to Health Information Technology, interoperability, information blocking, and cybersecurity Issues regarding the importance of Medicaid to children, including military and veteran families  Issues regarding Medicaid support for providers caring for children on Medicaid, including DSH payments Issues regarding Children's Hospitals Graduate Medical Education (CHGME) program and funding Issues related to 340B Drug Pricing Program, prescription drug pricing, drug shortages, high-cost drugs/therapies and pharmaceutical supply chain, including H.R. 3290 Issues related to pediatric workforce, Medicare GME, the Pediatric Specialty Loan Repayment Program, and Title VII and VIII Issues regarding Organ Procurement and Transplantation Network Issues regarding site neutrality, facility fees, and price transparency in health care  Issues regarding pediatric pandemic and disaster preparedness and response and emergency preparedness Issues regarding food security and nutrition Issues regarding drugs and medical device shortages and high costs, including IV fluid shortages and infant formula Issues related to the regulation of laboratory-developed tests Issues regarding prescribing of drugs via telehealth Issues related to mental health services in schools Issues related to pediatric cancer and the Moonshot Issues regarding Artificial Intelligence (AI) Issues regarding oversight and implementation of EPSDT H.R. 2412 The Helping Kids Cope Act S.2372/HR. 4758 - Accelerating Kids Access to Care Act  H.R. 1397, Telehealth Improvement for Kids Essential Services (TIKES) Act H.R. 7623/ S. 3967, Telehealth Modernization Act Issues involving Site Neutral payment legislation, including H.R. 3281 and H.R. 3561 S. 3029/H.R. 6085 PREEMIE Reauthorization Act H.R. 2584/S.2768, Safety form Violence for Healthcare employees (Save) Act S. 1409, Kids Online Safety Act H.R. 6663/S. 3364, Kid PROOF Act of 2023 H.R. 6664 Innovation for Pediatric Drugs Act of 2023 H.R. 7808, the Early Action and Responsiveness Lifts Youth (EARLY) Minds Act H.R. 7153/S. 3679 Dr. Lorna Breen Health Care Provider Protection Reauthorization Act S. 3757 Congenital Heart Futures Reauthorization Act of 2024 H.R. 6960 Emergency Medical Services for Children Reauthorization Act of 2024 H.R. 3391 Gabriella Miller Kids First Research Act 2.0 H.R. 6963 Pediatric Cancer Drug Supply Act H.R. 3433/ S. 2897, Give Kids A Chance Act H.R. 7384, Creating Hope Reauthorization Act. H.R. 6664/S. 4905, Innovation in Pediatric Drugs Act

Client expense: $1,600,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE

Issues related to S. 113, the Prescription Pricing for the People Act; S. 127, the Pharmacy Benefit Manager Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.1542/H.R. 6283, the Delinking Revenue from Unfair Gouging (DRUG) Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023 (previously H.R. 2691, Transparent PRICE Act); H.R. 3281, To promote hospital and insurer price transparency; H.R. 2880, Protecting Patients Against PBM Abuses Act; H.R. 2679, The PBM Accountability Act; H.R.3285, the Fairness for Patient Medications Act, to establish patient protections with respect to highly rebated drugs; H.R. 3262, To amend title XI of the Social Security Act to increase transparency of certain health-related ownership information; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 2666, the Medicaid VBPs for Patients (MVP) Act; H.R. 3284, the Providers and Payers COMPETE Act; S. 1967 the Patients Before Middlemen (PBM) Act; Protect Patients Access to Pharmacies Act; S. 2406, PBM Oversight Act of 2023; S. 2973, Modernizing and Ensuring PBM Accountability Act; S. 2436, the Neighborhood Options for Patients Buying Medicines (NO PBMs) Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2254, the Medicare PBM Accountability Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 4822, the Health Care Price Transparency Act of 2023; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 4508, the Hidden Fee Disclosure Act; H.R. 4507, the Transparency in Coverage Act of 2023; H.R. 4895, the Lowering Drug Costs for American Families Act; H.R. 5378 Lower Costs, More Transparency Act; H.R. 4527, Health Data Access, Transparency, and Affordability Act (DATA) Act; H.R. 3285, Fairness for Patient Medications Act; S. 2973 Modernizing and Ensuring PBM Accountability Act; S. 3548, Health Care Prices Revealed and Information to Consumers Explained Transparency Act (Health Care PRICE Transparency Act 2.0); H.R.3285 - Fairness for Patient Medications Act; H.R. 3008, the Drug Shortage Prevention Act of 2023; H.R. 3810, the Drug Origin Transparency Act of 2023; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act of 2023; H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 7535, Prescription Drug Supply Chain Pricing Transparency Act; S. 2305, Biosimilar Red Tape Elimination Act; H.R. 6986/S.3583, to address patent thickets; H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act; Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act); S.150, the Affordable Prescription Drug for Patients Act; S. 142, the Preserve Access to Affordable Generics and Biosimilars Act; S. 5503, H.R. 10362, the Patients Before Monopolies (PBM) Act; P.L. No: 118-158 and draft FY2025 Continuing Resolution, issues related to PBMs.

Client expense: $1,420,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

340B Drug Discount Program, eligibility waiver H.R. 3290 H.R. 2389, S.1302 - Resident Physician Shortage Reduction Act H.R. 3561 - PATIENT Act H.R. 2665 - Supporting Safety-Net Hospitals Act HR 7635 - 340B PATIENTS Act SUSTAIN 340B Act ACCESS 340B Act Graduate Medical Education Disproportionate Share Hospital (DSH) payments Childrens Health Insurance Program Medicare Dependent Hospital Program (MDH) Medicaid Low Volume Payments (LV) Federal Medical Assistance Percentage Extension Inpatient Prospective Payment System Outpatient Prospective Payment System Bad debt/charity care Hospital Outpatient Department payments Site Neutral Payment Policies Acute Hospital Care at Home Program Telehealth coverage

Client expense: $70,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Educational debt, student loans, loan repayment programs, dental school accreditation Reauthorization of the Higher Education Act (student loans, accreditation) H.R. 1202/S. 704, Resident Education Deferred Interest Act (REDI Act) H.R. 5710, Student Loan Refinancing and Recalculation Act Student Loan Refinancing Act HIV Epidemic Loan-Repayment Program Act H.R. 6077, POST GRAD Act S. 2172/H.R. 7814 Dental Loan Repayment Assistance Act Bio-Professionals Workforce Pilot Program National Health Service Corps Reauthorization Teaching Health Centers Graduate Medical Education H.R. 3561, PATIENT Act Rural Health Care Workforce Pathway Act S. 4169, the Primary Care Team Education Centers Act

Client expense: $390,000 · Firm income: Not reported

Government targets: Education, Dept of, HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Indian Health Service, SENATE

HR 7024 - Tax Relief for American Families and Workers Act of 2024 including issues related to providing tax incentives to promote economic growth, specifically the provision related to the immediate deduction of the cost of U.S. based research and investment investments; S 866 - American Innovation and Jobs Act including issues related to revising and expanding the deductibility of research and development expenditures to allow for the immediate expensing of such expenditures; HR 2673 - American Innovation and R&D Competitiveness Act of 2023 including issues related to eliminating the five-year amortization requirement for research and experimental expenditures, thus allowing continued expensing of such expenditures in the taxable years in which they are incurred; HR 5688 - Bipartisan HSA Improvement Act of 2023 including issues related to Health Savings Account modernization; HR 5687 - HSA Modernization Act of 2023 including issues related to Health Savings Account modernization; S 127/HR 3561 - Pharmacy Benefit Manager Transparency Act of 2023 including issues related to reform and prescription drug pricing

Client expense: $2,980,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822), Accelerating Kids Access to Care Act(HR 3089, S 1544) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R. 7623: Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.

Client expense: $560,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Sustainability of safety net health systems; social determinants of health; promoting coordinated care; support of telehealth policies; 340B Protect Act, H.R. 4390; H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 3281, the Transparent PRICE Act; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; and H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R. 5378, the Lower Costs, More Transparency Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 8247, the Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2024; H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; and H.R. 10337, Expanding the Health Care Workforce Act.

Client expense: $130,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Funding for Disproportionate Share Hospitals (Medicaid DSH); Funding for Medicare graduate medical education (GME); Medicare site neutrality policies; support of telehealth policies, including for audio-only telehealth services; H.R. 7053/S. 3792 - acute hospital care at home waiver flexibility; H.R. 1613, the Drug Price Transparency in Medicaid Act of 2023; H.R. 2665, the Supporting Safety Net Hospitals Act; H.R. 3561, the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act of 2023; H.R.3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program; H.R. 5378, the Lower Costs, More Transparency Act; H.R. 5860, the Continuing Appropriations Act, 2024 and Other Extensions Act; S.3548, the Health Care Prices Revealed and Information to Consumers Explained Transparency Act; H.R.6363, the Further Continuing Appropriations and Other Extensions Act, 2024; H.R. 2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024; H.R. 7463, Extension of Continuing Appropriations and Other Matters Act, 2024; H.R. 7327, the Protecting Front Line Multimission Hospitals Act of 2024; S. 3450, the Mental and Physical Health Care Comorbidities Act of 2023; and H.R. 10337, Expanding the Health Care Workforce Act.

Client expense: $130,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program H.R. 456: Fairness in Orphan Drug Exclusivity Act H.R. 830: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes H.R. 1613: Drug Price Transparency in Medicaid Act of 2023 H.R. 1790: Biologics Competition Act of 2023 - To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes H.R. 2534: PROTECT 340B Act of 2023 - Provisions related to the 340B program H.R. 2679: Pharmacy Benefits Manager Accountability Act H.R. 2707: MADE in America Act H.R. 2816: Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880: Protecting Patients Against PBM Abuses Act H.R. 3290: To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3433: Give Kids a Chance Act of 2024 H.R. 3561: Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or PATIENT Act of 2023 H.R. 3839: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act H.R. 4818: Treat and Reduce Obesity Act of 2023 H.R. 4895: Lowering Drug Costs for American Families Act - Provisions related to drug pricing H.R. 4988: Modern Authentication of Pharmaceuticals Act of 2023 H.R. 5376: Share the Savings with Seniors Act  H.R. 5378: Lower Costs, More Transparency Act H.R. 5391: Protecting Patient Access to Cancer and Complex Therapies Act H.R. 5539: ORPHAN Cures Act H.R. 6283: Delinking Revenue from Unfair Gouging or DRUG Act H.R. 6664: Innovation in Pediatric Drugs Act of 2023 H.R. 7174: Ensuring Pathways to Innovative Cures (EPIC) Act: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 7248: FDA Modernization Act 3.0 H.R. 7623: Telehealth Modernization Act of 2024 H.R. 7635: The 340B PATIENTS Act of 2024 H.R. 8574: 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act H.R. 9096: Pharmacists Fight Back Act S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs S. 148: Stop STALLING Act - Provisions related to citizen petitions S. 1067: Ensuring Timely Access to Generics Act of 2023 S. 1130: Health Care PRICE Transparency Act S. 1264: SMART Prices Act - Provisions related to drug pricing reform S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes S. 1497: Emergency Access to Insulin Act of 2023 S. 1542: Delinking Revenue from Unfair Gouging Act or DRUG Act - Provisions related to PBMs S. 1589: Safeguarding Patients and Taxpayers Act S. 1967: PBM Act S. 2305: Biosimilar Red Tape Elimination Act S. 2333: Pandemic and All-Hazards Preparedness and Response Act S. 2474: Share the Savings with Seniors Act S. 2973: Modernizing and Ensuring PBM Accountability Act S. 3393: SUPPORT for Patients and Communities Reauthorization Act S. 3430: Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S. 5021: 340B PATIENTS Act of 2024 S. 5040: Protecting Patients from Deceptive Drugs Online Act S. 5459: Biosimilars Access and Affordability Act BioCompete Act (draft) Executive Order of February 28, 2024, Preventing Access to Americans' Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) User fee policy issues Inflation Reduction Act of 2022 (P.L. 117-169) IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Cancer Moonshot Initiative 21st Century Cures 2.0 Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Accelerated approval policy issues FDA regulatory approval authority policy issues Competition policy issues Orphan Drug Act policy issues Compounding policy issues Antimicrobial resistance (AMR) policy issues Supply chain policy issues Clinical trial diversity policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Pandemic preparedness policy issues Artificial intelligence policy issues

Client expense: $7,560,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.2665, Supporting Safety Net Hospitals Act H.R.2389, the Resident Physician Shortage Reduction Act of 2023 H.R.3561 - PATIENT Act of 2023 H.R. 3887, the Childrens Hospital GME Support Reauthorization Act of 2023 H.R. 3561, PATIENT Act of 2023 H.R. 5378, The Lower Costs, More Transparency Act S. 2719 Directing our Countrys Transfer of Residency Slots (DOCTORS) Act of 2023 S. 3196 - Ensuring Medicaid Continuity for Children in Foster Care Act H.R. 2829 Chronic Care Management Improvement Act of 2023 H.R. 7397 -Reinforcing Essential Health Systems for Communities Act H.R. 6929 & S.3565, Affordable Connectivity Program Extension Act of 2024 Strengthening Pathways to Health Professions Act Fiscal Year 2025 Children's Hospitals Graduate Medical Education (CHGME) Appropriations Support Issues related to Section 203 of the Consolidated Appropriations Act of 2021 Issues related to the Medicare/Medicaid dual eligible population Issues related to Medicare Site-neutral payment cuts Issues related to Medicaid DSH Cuts

Client expense: $870,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

340B Program; Issues related to affordable prescription drugs; Issues related to health care workforce and staffing; Issues related to health care privacy; Issues related to telehealth authorities; Issues related to hospital price transparency; Issues related to hospital reimbursement; Issues related to nonprofit hospital practices; Issues related to hospital outpatient department payments; Issues related to hospital outpatient department payments; Medicaid Disproportionate Share Hospital payment adjustment program; Issues related to Medicare payments; Issues related to Medicare Advantage payment and prior authorization; Childrens Hospital Graduate Medical Education Program (CHGME); issues related to childrens medical care; issues related to rural health; S. 4352/H.R. 8702, the Seniors Timely Access to Care Act H.R. 2584/S. 2768, the Safety From Violence for Healthcare Employees (SAVE) Act; Expanding Care in the Home Act; H.R. 1770, Equitable Access to Pharmacy Services Act; issues related to Program for All-Inclusive Care for the Elderly (PACE); H.R. 1770, Equitable Access to Pharmacy Services Act; H.R. 3008, the Drug Shortage Prevention Act; H.R. 3810, the Drug Origin Transparency Act; H.R. 3793, the Ensuring Access to Lifesaving Drugs Act; issues related to preventing and mitigating drug shortages; H.R. 2389/S. 1302, the Resident Physician Shortage Reduction Act; H.R. 3263, the Support Faculty and Expand Access to Nursing Act; issues related to prior authorization, unwarranted claim denials, and payment delays; S. 2840, the Bipartisan Primary Care and Health Workforce Expansion Act; H.R. 3561, the PATIENT Act; H.R. 6363, Further Continuing Appropriations and Other Extension Act; H.R. 5378, the Lower Costs, More Transparency Act; Issues related to mental and behavioral health; the limit on Medicare payment days for inpatient psychiatric care; the Institutions for Mental Disease exclusion; issues related to extending programs under the SUPPORT for Patients Communities Act; issues related to cybersecurity; enhanced Advanced Premium Tax Credits

Client expense: $750,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to affordable prescription drugs; Issues related to telehealth authorities; Issues related to health care workforce and staffing; Medicaid Disproportionate Share Hospital payment adjustment program; Issues related to Medicaid coverage; Issues related to hospital reimbursement; 340B Program; Issues related to hospital price transparency; Issues related to Medicare payments; Issues related to Medicare Advantage payment and prior authorization; issues related to rural health reimbursement, including the Medicare Dependent Hospital and Low Volume Hospital programs; physician reimbursement rates; S. 4352/H.R. 8702, the Seniors Timely Access to Care Act; issues related to Program for All-Inclusive Care for the Elderly (PACE); issues related to improving coordination of care for dual eligibles; issues related to site neutral payments; H.R. 3281, the Transparent PRICE Act; issues related to prior authorization, unwarranted claim denials, and payment delays; the Biologics Price Competition and Innovation Act (BPCIA); H.R. 3561, the PATIENT Act; H.R. 6363, Further Continuing Appropriations and Other Extension Act; H.R. 5378, the Lower Costs, More Transparency Act; PL 118-42/H.R. 4366 - Consolidated Appropriations Act, 2024; PL 118-47/H.R. 2882 - Consolidated Appropriations Act, 2024; Issues related to mental and behavioral health; the limit on Medicare payment days for inpatient psychiatric care; the Institutions for Mental Disease exclusion; issues related to extending programs under the SUPPORT for Patients Communities Act; H.R. 10545, the American Relief Act

Client expense: $750,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Medicare/Medicaid reimbursement Accountable, value-based care CMMI to discuss payment models. Health insurer practices (denials, prior authorization) Telehealth flexibilities HR 2389 Resident Physician Shortage Reduction Act HR 468 Building America's Healthcare Workforce Act HR 2665 Supporting Safety Net Hospitals Act S. 1869 SITE Act S. 2016/HR 4189 Connect for Health Act S. 2187/HR 5128 Preserving Access to Home Health Act HR 3561 Patient Act S. 1845 Expanding Access to Palliative Care Act HR 5013 Value in Health Care Act HR 3459, S. 1703 PACE Part D Choice Act HR 2474 Strengthening Medicare for Patients and Providers Act Minimum staffing standards for LTC facilities HR 6545 Physician Fee Schedule Update and Improvements Act HR 6683 Preserving Seniors Access to Physicians Act HR 6590 PACE Expanded Act S. 3892 Community Health Worker Access Act HR 7513 Protecting America's Seniors' Access to Care Act S. 4330 Radiation Oncology Case Rate (ROCR) Value Based Program Act S. 4532/HR 8702 Improving Seniors Timely Access to Care Act Medicare Advantage star ratings S. 3967/HR 7623Telehealth Modernization Act

Client expense: $200,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), SENATE

Legislation affecting the regulation of private equity, including H.R. 3262, H.R. 3561, and other proposals related to equitable treatment of private equity in health care.

Client expense: $690,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S.652 - Safe Step Act (Murkowski/Hassan), support passage H.R. 830 - HELP Copays Act, support passage S.935- Fair Accountability and Innovative Research Drug Pricing Act of 2023, support passage H.R. 485, Protecting Health Care For All Patients Act, oppose passage as currently written S.127, the Pharmacy Benefit Manager Transparency Act, support passage Urged HELP and House Energy and Commerce Committee to hold roundtables and advance proposals that address workforce issues within the healthcare community. S. 2333 - Pandemic and All-Hazards Preparedness and Response Act, support passage H.R. 824, Telehealth Benefit Expansion for Workers Act of 2023, oppose passage H.R. 4421, Preparing for All Hazards and Pathogens Reauthorization Act, monitor legislation H.R. 4420, Preparedness and Response Reauthorization Act, monitor legislation Committee Draft -The Primary Care and Health Workforce Expansion Act, support passage S. 1339, the Pharmacy Benefit Manager Reform Act, support passage S.127, the PBM Transparency Act of 2023, support passage S.113, The Prescription Pricing for the People Act of 2023, support passage S.2052, Protect Patient Access to Pharmacies Act H.R. 1692, Health Care Affordability Act of 2023 H.R. 3561, the PATIENT Act of 2023, support passage H.R. 3284, Providers and Payers Compete Act, support passage H.R. 4507, Transparency in Coverage Act, support passage H.R. 4508, Hidden Fee Disclosure Act, support passage H.R. 2816, PBM Sunshine and Accountability Act, support passage S.79- Interagency Patent Coordination and Improvement Act of 2023, support passage S. 142- Preserve Access to Affordable Generics and Biosimilars Act, support passage S.148- Stop STALLING Act, support passage S.150- Affordable Prescriptions for Patients Act of 2023, support passage S.775-Increasing Transparency in Generic Drug Applications Act, monitoring S.1067-Ensuring Timely Access to Generics Act of 2023, support passage S. 2780 Medication Affordability and Patent Integrity Ac H.R. 4189, the CONNECT for Health Act, support passage H.R. 1843, the Telehealth Expansion Act, support passage H.R. 8018, the Alleviating Barriers for Caregivers Act, support passage S. 3109, the Alleviating Barriers for Caregivers Act, support passage H.R.6302, the Health Share Transparency Act of 2023 H.R.7623, the Telehealth Modernization Act of 2024

Client expense: $51,247 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to rural health, including Low-Volume Hospital and Medicare Dependent Hospital programs, hospital reimbursement, including sequestration, prescription drug pricing, surprise billing, telehealth, 1115 Medicaid Waiver, health care workforce, maternal health, and freestanding ERs; H.R.1694 - Emergency Care Improvement Act; Implementation of the Consolidated Appropriations Act, 2023 (P.L. 117-328); Disproportionate Share Hospital (DSH) payments; H.R.2665 - Supporting Safety Net Hospitals Act; Site-neutral payment policies; H.R.3561 - PATIENT Act of 2023; H.R.5378 - Lower Costs, More Transparency Act; S.2840 - Bipartisan Primary Care and Health Workforce Act; S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023.

Client expense: Not reported · Firm income: $110,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE